3.0核磁共振在前列腺癌术前诊断及分期中的应用价值  

Value on 3.0 Nuclear Magnetic Resonance(NMR) of Preoperative Diagnosis and Staging of Prostate Cancer

作　　者：王锋[1] 倪文君[1] 赵淼[1] 

机构地区：[1]黑龙江省医院泌尿外科,黑龙江哈尔滨150030

出　　处：《中国继续医学教育》2016年第14期46-47,共2页China Continuing Medical Education

摘　　要：目的分析3.0核磁共振在前列腺癌术前诊断及分期中的应用价值。方法选取我院56例经手术病理证实的前列腺癌患者,所有患者给予3.0核磁共振扫描和CT扫描,核磁共振保护T_1WI、T_2WI扫描、FSPGR抑制,CT给予动态增强扫描等。结果核磁共振术前T分期准确度96.4%、淋巴结转移敏感度38.5%,CT术前T分期准确度83.9%、淋巴结转移敏感度19.2%,两者术前T分期准确度、淋巴结转移敏感度差异有统计学意义(P<0.05)。结论针对前列腺癌诊断、术前分期,核磁共振诊断价值明显优于CT,值得临床推广应用。Objective To analyze the clinical value of 3 nuclear magnetic resonance imaging in the preoperative diagnosis and staging of prostate cancer. Methods 56 cases of prostate cancer patients after surgical certification were selected in our hospital. All patients were given 3.0 MRI and CT scans, inhibition of nuclear magnetic resonance protection T1WI and T2WI and FSPGR CT dynamic enhancement scan. Results Preoperative T staging accuracy was 96.4%, lymph node metastasissensitivity was 38.5%, Preoperative T staging accuracy of CT was 83.9%, lymph node metastasis sensitivity was 19.2%. There were significant in Preoperative T staging accuracy and lymph node metastasis specificity（P〈0.05）. Conclusion The diagnosis and preoperative staging of prostate cancer, the value of MRI is better than CT, which is worth to be popularized and applied.

关 键 词：3.0核磁共振 前列腺癌 术前诊断 分期 

分 类 号：R737.25[医药卫生—肿瘤]